Ferumoxytol: An effective and safe remedy for iron deficiency anemia
https://medicaldialogues.in/medicine/news/ferumoxytol-an-effective-and-safe-remedy-for-iron-deficiency-anemia-finds-study-69861
Iron
deficiency anemia is the most common form of anemia and hematologic problem
worldwide. Treatment options include oral or intravenous (IV) iron replacement.
Although oral iron is commonly employed as first-line therapy, many studies
suggest that IV iron more effective and associated with a better quality of
life when compared to oral iron. Yet, adverse infusion reactions are possible.
here are multiple intravenous (IV) iron formulations available, of which
several may be administered as single‐dose infusions such as
low-molecular-weight iron dextran (LMWID), ferumoxytol, ferric carboxymaltose,
and ferric derisomaltose. However, the administration of ferumoxytol as a
single‐dose infusion is off‐label as it is approved as a 2‐dose series.
Researchers have found in a new study that the use of single-dose ferumoxytol
for the treatment of iron deficiency anemia appears to be safe and effective
compared with single-dose low molecular weight iron dextran, with a similar
efficacy profile and a reduced need for repeated IV iron infusions.
Single‐dose ferumoxytol is considered
effective and safe, and those patients may require fewer additional infusions
compared to patients who received low-molecular-weight iron dextran (LMWID),
according to recent research published in the America Journal of Hematology.
Although
previous studies of ferumoxytol alone support the effectiveness and safety of
the single‐dose
regimen, there is a paucity of data directly comparing single‐dose ferumoxytol to other single‐dose IV iron formulations, he adds.
In his study, Jonathan and his colleagues included an overall of 906 patients
who received single‐dose LMWID or ferumoxytol, and all these patients were
included for the secondary analysis evaluating the incidence of adverse events
(AE) and the requirement of additional IV iron infusions.
The findings of the research are-
a. Median change in Hb, Hct, and ferritin was not significantly different between groups.
b. Both groups experienced similar rates of AEs.
c. LMWID patients more frequently required additional IV iron infusions.
Based on
the results, the researchers conclude that "single‐dose ferumoxytol is effective and
safe compared to patients who received LMWID for the treatment of iron
deficiency."